• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy.

作者信息

Bruder Jan M

机构信息

Department of Medicine, Division of Endocrinology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.

出版信息

Curr Urol Rep. 2005 May;6(3):157-8. doi: 10.1007/s11934-005-0001-x.

DOI:10.1007/s11934-005-0001-x
PMID:15869718
Abstract
摘要

相似文献

1
Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy.接受雄激素剥夺治疗的前列腺癌男性骨质疏松症管理实用指南。
Curr Urol Rep. 2005 May;6(3):157-8. doi: 10.1007/s11934-005-0001-x.
2
Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.双膦酸盐用于预防接受前列腺癌雄激素剥夺治疗的男性骨质疏松症。
Drugs Aging. 2003;20(3):175-83. doi: 10.2165/00002512-200320030-00002.
3
Calcium supplements in patients with prostate cancer.前列腺癌患者的钙补充剂
BJU Int. 2007 Dec;100(6):1411. doi: 10.1111/j.1464-410X.2007.07298_1.x.
4
Osteoporosis from androgen deprivation therapy in prostate cancer treatment.前列腺癌治疗中雄激素剥夺疗法所致的骨质疏松症。
Aust Fam Physician. 2006 Apr;35(4):243-5.
5
Bisphosphonates in prostate cancer: where are we and where should we go?
J Natl Cancer Inst. 2003 Sep 3;95(17):1262-3. doi: 10.1093/jnci/djg062.
6
The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.双膦酸盐在接受雄激素剥夺治疗的前列腺癌男性患者中的作用。
Oncology (Williston Park). 2004 May;18(5 Suppl 3):21-5.
7
Osteoporosis and prostate cancer.骨质疏松症与前列腺癌。
Br J Cancer. 2003 Sep 1;89(5):779-80. doi: 10.1038/sj.bjc.6601191.
8
Approach to the prostate cancer patient with bone disease.前列腺癌骨病患者的治疗方法。
J Clin Endocrinol Metab. 2008 Jan;93(1):2-7. doi: 10.1210/jc.2007-1402.
9
[Prevention of osteoporosis--important for the urologist?].[骨质疏松症的预防——对泌尿外科医生重要吗？]
Urologe A. 2007 Jun;46(6):651-5. doi: 10.1007/s00120-007-1349-y.
10
Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.双膦酸盐在预防与雄激素剥夺治疗相关的骨并发症方面有效。
J Support Oncol. 2006 Feb;4(2):99-100.

本文引用的文献

1
Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.雄激素剥夺治疗期间前列腺癌男性患者基于中央和外周骨矿物质密度的骨质减少和骨质疏松患病率
Urology. 2006 Jan;67(1):152-5. doi: 10.1016/j.urology.2005.07.017.
2
Risk of fracture after androgen deprivation for prostate cancer.前列腺癌雄激素剥夺治疗后的骨折风险。
N Engl J Med. 2005 Jan 13;352(2):154-64. doi: 10.1056/NEJMoa041943.
3
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
唑来膦酸预防非转移性前列腺癌雄激素剥夺治疗男性骨质流失的随机对照试验。
J Urol. 2003 Jun;169(6):2008-12. doi: 10.1097/01.ju.0000063820.94994.95.
4
Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.接受促性腺激素释放激素类似物治疗的前列腺癌男性患者性腺功能减退后的骨质流失。
J Clin Endocrinol Metab. 2002 Aug;87(8):3656-61. doi: 10.1210/jcem.87.8.8782.
5
Implications in the use of T-scores for the diagnosis of osteoporosis in men.T评分在男性骨质疏松症诊断中的应用意义。
J Clin Densitom. 2002 Spring;5(1):87-93. doi: 10.1385/jcd:5:1:087.
6
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.帕米膦酸盐预防前列腺癌雄激素剥夺治疗期间的骨质流失。
N Engl J Med. 2001 Sep 27;345(13):948-55. doi: 10.1056/NEJMoa010845.
7
Alendronate for the treatment of osteoporosis in men.阿仑膦酸钠用于治疗男性骨质疏松症。
N Engl J Med. 2000 Aug 31;343(9):604-10. doi: 10.1056/NEJM200008313430902.
8
Discordance in patient classification using T-scores.使用T值进行患者分类时的不一致性。
J Clin Densitom. 1999 Fall;2(3):343-50. doi: 10.1385/jcd:2:3:343.
9
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.骨折风险评估及其在绝经后骨质疏松症筛查中的应用。世界卫生组织研究小组报告。
World Health Organ Tech Rep Ser. 1994;843:1-129.